Effect of metoclopramide on plasma catecholamine release in essential hypertension.
The catecholamine (CA)-releasing action of metoclopramide (MCP) observed in patients with pheochromocytoma was tested in 20 subjects with essential hypertension and compared with the same effect of glucagon in 10 of them. We found that even in the absence of pheochromocytoma, MCP is a CA-releasing substance, moderately increasing systolic blood pressure and pulse rate. The release of CA is reflected by an increase in concentrations of free norepinephrine and total (free plus sulfated) epinephrine 3 minutes and of total dopamine and norepinephrine 10 minutes after the MCP bolus dose, whereas glucagon had an effect on the release of free epinephrine. Regional catheterization before and after MCP dosing in one subject showed a considerable increase in adrenal epinephrine and norepinephrine concentrations 45 seconds after the MCP bolus dose. MCP has a free CA-releasing potency much like that of glucagon. Because the released free CA is readily sulfoconjugated, the effect on CA release can be more easily detected when conjugated CA is determined. MCP should thus be used with caution in pheochromocytoma as well as in other forms of hypertension.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000097:blood / Q000378:metabolism*; D002404:Catheterization; D004298:Dopamine / Q000097:blood; D004341:Drug Evaluation; D004837:Epinephrine / Q000097:blood; D005260:Female; D005934:Glucagon / Q000494:pharmacology*; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000378:metabolism*; D007275:Injections, Intravenous; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology*; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D010673:Pheochromocytoma / Q000175:diagnosis / Q000378:metabolism*; D011674:Pulse / Q000187:drug effects
D002395:Catecholamines; D005934:Glucagon; D008787:Metoclopramide; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine